Results 630 patients have outcomes recorded. We report on 370 who have completed treatment. 81% male, mean age 68 years (40–91). Patient's underwent mean 2.5 ablations (1–6) during protocol. 70% baseline histology HGD, 27% IMC & 3% LGD. Mean length baseline BE 5.6cm (1–20). At 12 months CR-HGD was 87% patients, CR-D 82%, & CR-BE 64%. 97% with no dysplasia at 12 months remain disease free at most recent follow up (median 18 months, range 2–68). Kaplan Meier statistics predict CR-D is durable at 5 years with 88% remaining disease free. Logistic regression demonstrate each extra 1 cm of BE reduces chances of attaining CR-D by 15.7% (OR 1.156, SE 0.048, CI 1.07–1.26, $p = 0.0003$) & for each extra RFA treatment likelihood of CR-D increases by 31.7% (OR = 0.683, SE 0.95, CI 0.52–0.89, $p = 0.0006$). Progression to invasive cancer at 12 months is 2.7%. Symptomatic strictures requiring dilatation occurred in 9% after treatment.

Conclusion End of protocol CR-D is encouraging at 83% & successful eradication appears durable. Patients with shorter segment BE respond better & multiple treatments are more likely to achieve CR-D. Our data represent real life outcomes of integrating novel endotherapy into demanding endoscopy service commitments

Disclosure of Interest None Declared

OC-052 COMBINED EMR AND RADIO FREQUENCY ABLATION LEADS TO HIGH BARRETT'S ERADICATION RATES FOLLOWING STRUCTURED TRAINING PROGRAMME

doi:10.1136/gutjnl-2013-304907.051

¹J Faulkner, ¹R Ley Greaves, ^{1,2}J Hoare. ¹Gastroenterology, Imperial College London, London, UK

Introduction EMR and Radio Frequency Ablation (RFA) have recently been combined to treat dysplastic Barrett's oesophagus (1). These are complex techniques and require a high level of endoscopic skill and published reports show a range of success. The Academic Medical Centre (AMC) in Amsterdam is a high volume tertiary centre for these procedures and has established expertise in providing structured teaching (2). After attending a structured teaching programme at the AMC a service was established at a London teaching hospital to treat patients with dysplastic Barrett's oesophagus. We wanted to know if high quality results could be reproduced in this setting.

Methods We retrospectively analysed all cases of dysplastic Barrett's referred for treatment at our centre since the introduction of RFA (Barryx), following structured training at the AMC. Decision for endoscopic therapy was made at a multidisciplinary meeting involving surgeons, radiologists, oncologists and gastroenterologists. Published protocols for treatment with EMR/RFA were closely followed (1), although argon plasma coagulation was used to remove residual islands less than 5mm in the interests of cost, rather than RFA. All procedures were carried out by one of two senior endoscopists.

Results Over 30 months 33 patients were referred for endoscopic therapy. Following initial EMR of visible lesions 3 were found to have cancer extending beyond the first 1/3 of the sub-mucosa and were offered alternative therapy. 24 have finished therapy and 1 is lost to follow up. Mean age was 70 years (53–89) and mean Barrett's length 5.4cm (<1–10cm). Therapy was applied as follows: 2 patients had only EMR, 4 only RFA, 1 EMR + APC, 6 EMR + RFA, 5 RFA + APC, 6 EMR + RFA + APC. 24/24 have had eradication of high grade dysplasia or intra-mucosal cancer (100%). 21/24 (87.5%) have had complete eradication of Barrett's by endoscopic and histological criteria. Mean follow up is 9.8 months (1.5–25). There were no perforations. 3 strictures were treated endoscopically.

Conclusion Following a comprehensive structured teaching programme in the treatment of dysplastic Barrett's with combined RFA and EMR, results comparable to published studies are achievable in lower volume centres treating approximately only one new patient per month.

Disclosure of Interest None Declared

REFERENCES

1. Radiofrequency ablation for total Barrett's eradication: a description of the endoscopic technique, its clinical results and future prospects. Pouw RE *et al.* Endoscopy. 2008 Dec; 40(12):1033–402.
2. Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training programme. Van Vilsteren FG *et al.* Endoscopy. 2012 Jan; 44(1):4–12.

Liver symposium: impact of clinical research in hepatology

OC-053 CURCUMIN, ANTI-OXIDANT, AND PIOGLITAZONE THERAPY WITH INCLUSION OF VITAMIN E IN NON ALCOHOLIC FATTY LIVER DISEASE-A RANDOMIZED OPEN LABEL PLACEBO CONTROLLED CLINICAL PROSPECTIVE TRIAL (CAPTIVE)

doi:10.1136/gutjnl-2013-304907.052

^{1,2}P Basu, ³N J Shah, ²S Farhat, ¹R Siriki, ¹K Mittimanj, ¹S Atluri, ¹M Rahaman. ¹Forest Hills Hospital, Hofstra North Shore-LIJ School of Medicine; ²Columbia School of Physicians and Surgeons, NY; ³James J Peters VA Medical Center, Mount Sinai School of Medicine, New York, New York, United States

Introduction NAFLD is a global clinical challenge which progresses to cirrhosis and liver cancer. Defective transport of free fatty acids and mitochondrial dysfunction lead to explosion of a series of free radicals, apoptosis, up regulated cytokines and fibrogenesis ultimately causing cirrhosis and cancer. Curcumin is a pan-antioxidant with anti-inflammatory, anti-apoptotic, anti-microbial, and anti-fibrogenic properties. This study evaluates the role of curcumin in NAFLD to progression of NASH

Methods Eighty patients (n = 80) with mean BMI 29%, NAFLD score 0.66, NASH fibrotic score 0.33, HOMA IR 3.8, ALT 58, LDLc 143, HDLc 29, Triglyceride 186 and Adipokines (leptin, Adiponectin, Retinol Binding Proteins) were divided into Group A (n = 20) pioglitazone 15mg, Group B (n = 20) vitamin E, Group C (n = 20) curcumin (all the three above groups received placebo), and Group D (n = 20) vitamin E plus curcumin. Pre and post values (Triglycerides, LDLc, HDLc, ALT, HOMA-IR, TNF- α , Leptin, Adiponectin, Retinol Binding Protein, HbA1c, Serum necro-inflammatory NAFLD and NASH fibrotic score were analysed at 3, 6, and 12 months. Diet and exercise were left unchanged. Daily alcohol content was less than 30 grammes

Results Group A-Minimal changes on ALT, HbA1c, HOMA, lipids, no changes in TNF- α , adipokines, lipid profile and necro-inflammatory score and/or NASH fibrosis score. Group B and Group C had modest changes in ALT, lipid profile, HbA1c and HOMA; while no changes in adipokines, necro-inflammatory score and fibrotic score. Group D had significant changes in all scores particularly the adipokines and small improvements in fibrotic score. All patients tolerated the medications well

Conclusion This study postulates the effects of Curcumin plus vitamin E in NAFLD may prevent NASH with a modest anti-fibrotic effects and necro-inflammatory score; with impressive changes in adipokines levels. Additive effects of Curcumin with vitamin E has significant effects on Serum lipids and insulin sensitivity. Unavailability of Pre and post liver biopsy was the limitation A large control trial needs to validate.

Disclosure of Interest None Declared

OC-054 HEPATIC EXPRESSION OF CCL25 MEDIATES RECRUITMENT OF PLASMACYTOID DENDRITIC CELLS TO LIMIT LIVER INJURY

doi:10.1136/gutjnl-2013-304907.053

¹D Reid, ²V Lai, ³C Weston, ¹T Vo, ⁴M Peters, ³D Adams, ^{1,2}B Eksteen. ¹Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada; ²Asian Centre for Liver Disease & Transplantation, Singapore, Singapore; ³Centre for Liver Research, NIHR Biomedical Research Unit, University of Birmingham, Birmingham, UK; ⁴University of California, San Francisco, United States